Study on the medication rule of Professor Shen Shaogong in the diagnosis and treatment of lung cancer

ZHANG Han; LI Yukun; LIU Dasheng; WANG Feng; HAN Xuejie

doi:10.3969/j.issn.2095-6606.2023.06.020

您当前的位置：

首页 >

文章列表页 >

Study on the medication rule of Professor Shen Shaogong in the diagnosis and treatment of lung cancer

Literature Research | 更新时间：2023-12-08

- Study on the medication rule of Professor Shen Shaogong in the diagnosis and treatment of lung cancer
- Modern Chinese Clinical Medicine Vol. 30, Issue 6, Pages: 91-95(2023)
- 作者机构：
  
  1.中国中医科学院广安门医院老年科　北京　100053
  2.中国中医科学院中医临床基础医学研究所
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.2095-6606.2023.06.020
  CLC： R273
- Published：30 November 2023，
  
  Received：16 September 2022，
- 稿件说明：
移动端阅览
ZHANG Han, LI Yukun, LIU Dasheng, et al. Study on the medication rule of Professor Shen Shaogong in the diagnosis and treatment of lung cancer. [J]. Modern Chinese Clinical Medicine 30(6):91-95(2023)
DOI：

ZHANG Han, LI Yukun, LIU Dasheng, et al. Study on the medication rule of Professor Shen Shaogong in the diagnosis and treatment of lung cancer. [J]. Modern Chinese Clinical Medicine 30(6):91-95(2023) DOI： 10.3969/j.issn.2095-6606.2023.06.020.

摘要

目的

分析沈绍功教授诊治肺癌的用药规律。

方法

110首处方均为2015年1月—2017年12月沈教授治疗肺癌患者的有效首诊方，对中药名称进行统一规范、数据整理，采用关联规则Apriori算法和Cytoscape数据分析方法，总结诊治肺癌的用药规律。

结果

110首处方共涉及肺癌患者110例，其中，男性12例，女性98例。最大年龄82岁，最小年龄35岁，平均年龄(61.17±7.69)岁。使用频次>17的单味药物，共30味，排名前15位的药物主要为沈教授治疗肺癌阴阳两虚证的主方调肾阴阳方(枸杞子10 g，野菊花10 g，生地黄10 g，黄精10 g，生杜仲10 g，桑寄生10 g)。对处方中支持度>15%的单味药进行分类统计，其中，补阴药平均频次最高，为2.58。按支持度排列，前6位依次为枸杞子－仙鹤草、黄精－仙鹤草、枸杞子－黄精、白花蛇舌草－枸杞子、白花蛇舌草－黄精、枸杞子－生地黄。置信度均为100%的药对有16个。支持度>10%的药物组合可视化网络分析结果显示，解毒、利湿、补阳、补阴、补血、燥湿和止血为主要使用目的。

结论

沈教授针对肺癌用药思路重在顾护脾胃、调肾阴阳，兼解毒化湿。

Abstract

Objective

To analyze the rule of medication in the diagnosis and treatment of lung cancer by Professor Shen Shaogong.

Methods

The 110 formulas included in this study were all prescribed by Professor Shen for the patients at their first visits for the treatment of lung cancer from January 2015 to December 2017

and proven to be effective. The names of the herbs used were standardized and data were collected. Association rule Apriori algorithm and Cytoscape data analysis were employed to summarize the medication rules for the diagnosis and treatment of lung cancer.

Results

110 patients with lung cancer were involved in the 110 formulas

including 12 males and 98 females. The maximum age was 82 years

the minimum age was 35 years

and the mean age was (61.17±7.69)years. There were 30 single herbs with a frequency of > 17

and the top 15 herbs were Tiaoshen Yinyang Formula (Kidney-Yin-Yang-Regulating Formula) (10 g Gouqizi(Fructus Lycii)

10 g Yejuhua (Flos Chrysanthemi Indici)

10 g Shengdihuang (Radix Rehmanniae)

10 g Huangjing (Rhizoma Polygonati)

10 g Shengduzhu (Cortex Eucommiae)

10 g Sangjisheng (Herba Taxilli))

which was the main prescription used by Professor Shen to treat yin-yang deficiency syndrome of lung cancer. The average frequency of yin-tonifying herbs was the highest

which was 2.58. According to the degree of support

the top 6 were Gouqizi-Xianhecao (Herba Agrimoniae)

Huangjing-Xianhecao

Gouqizi-Huangjing

Baihuasheshecao (Herba Hedyotis Diffusae) - Gouqizi

Baihuasheshecao - Huangjing

Gouqizi - Shengdihuang. There were 16 herb pairs with 100% confidence. The result of the visual network analysis of herbal combinations with support > 10% showed that the main purposes were resolving toxins

draining dampness

supplementing yang

supplementing yin

supplementing the blood

drying dampness and stanching bleeding.

Conclusion

Professor Shen’s ideas of medication for lung cancer mainly focus on protecting the spleen and stomach

regulating kidney yin and yang

and resolving toxins and dampness.

关键词

肺癌核心处方用药规律临床经验沈绍功

Keywords

lung cancercore prescriptionmedication ruleclinical experienceShen Shaogong

references

潘昊. 中国部分地区肺癌早诊早治筛查项目肺癌患者的预后、经济负担及筛查策略的卫生经济学评价与分析[D]. 沈阳：中国医科大学，2022.

CRYER A M，THORLEY A J. Nanotechnology in the diagnosis and treatment of lung cancer[J/OL]. Pharmacol Ther，2019, 198: 189-205[2022-08-16]. https://pubmed.ncbi.nlm.nih.gov/30796927/https://pubmed.ncbi.nlm.nih.gov/30796927/.

SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021, 71(3): 209-249.

XIA C，DONG X，LI H，et al. Cancer statistics in China and United States，2022：profiles，trends，and determinants[J]. Chin Med J，2022, 135(5): 584-590.

国家药典委员会. 中华人民共和国药典：2020年版.一部[M].北京：中国医药科技出版社, 2020.

国家中医药管理局《中华本草》编委会. 中华本草[M].上海：上海科学技术出版社, 1999.

董琳，权洪峰，周希蓉，等.基于关联规则apriori算法的黄芪方剂配伍规律研究[J].亚太传统医药，2020, 16(11): 151-155.

钟赣生，杨柏灿. 中药学[M]. 5版.北京：中国中医药出版社, 2021.

吴心语，李和根.中医扶正治疗肺癌对免疫调节作用的研究进展[J].世界中西医结合杂志，2022, 17(8): 1691-1696.

刘莹. 白花蛇舌草通过Nrf2/HO－1通路对肺腺癌增殖和侵袭的作用研究[D]. 南昌：南昌大学，2023.

彭丽蓉，彭海燕. 仙鹤草抗癌作用的临床与实验研究进展[J].中华中医药杂志，2022, 37(7): 3992-3994.

王中华，郭庆梅，周凤琴. 芦根化学成分、药理作用及开发利用研究进展[J].辽宁中医药大学学报，2014, 16(12): 81-83.

龚发萍，郑鸣.黄芩的化学成分及药理作用[J]. 临床合理用药杂志，2021, 14(34): 176-178.

李晓凯，顾坤，梁慕文，等.薏苡仁化学成分及药理作用研究进展[J].中草药，2020, 51(21): 5645-5657.

张海璐，刘宇恒.中医药治疗肺癌临床研究进展[J].内蒙古中医药，2023, 42(4): 156-158.

刘玉才，王永锋，赵立江，等.中医药联合化疗治疗晚期非小细胞肺癌临床研究进展[J].中国中医药现代远程教育，2023, 21(18): 193-196.

罗智杰，戴梓，廖培，等.基于网络药理学探索仙鹤草治疗肺癌的分子机制[J].中医肿瘤学杂志，2023, 5(2): 71-80.

李梓盟，张佳彦，李菲，等.白花蛇舌草抗肿瘤化学成分及药理作用研究进展[J].中医药信息，2021, 38(2): 74-79.

贾羲，王娟，贾文瑞，等.白花蛇舌草多糖对Lewis肺癌小鼠肿瘤抑制作用及机制研究[J].中医学报，2021, 36(1): 143-147.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

沈绍功教授治疗不孕症临床用药规律研究

Literature study on medication rule and dose-effect relationship of Gegen Qinlian Decoction(Pueraria Root, Scutellaria Root, and Coptis Decoction)

TCM pathogenesis and syndrome manifestations of cancer-related fatigue in patients with lung cancer

Exploring the influence of intestinal flora on lung cancer based on the theory of "the interior-exterior relationship between the lung and large intestine"

Analysis of Chinese medicine in treating acne vulgaris based on data mining

Related Author

沙正华

李静

黄雪琪

王莹莹

韩学杰

杨金生

YANG Yidian

ZHAO Yuqing

Related Institution

Exchange and Cooperation Center of Taiwan Hong Kong and Macao, State Administration of TCM

Beijing University of Chinese Medicine

The Second Clinical College of Beijing University of Chinese Medicine

The First Medical College of Guangzhou University of Chinese Medicine

Shenzhen Hospital (Longgang) Beijing University of Chinese Medicine

⁰